Melanoma and Skin Cancer Trials and the Victorian Heart Institute are leading an Australian-first trial to determine if a common cholesterol medication can reduce the risk of heart attacks in melanoma patients treated with cancer therapy.
A $110,000 donation to a new trial treating melanoma brain metastases will help open additional research sites around Australia, offering hope to patients, like Peter Wilson, who have melanoma that has spread to the brain.
MASC Trials, MSCAN and BlazeAid have partnered to deliver sun safety educational videos for BlazeAid volunteers so they know how to protect their skin during frontline disaster response work.
Digital photography combined with artificial intelligence technology has shown promising results as a diagnostic tool for the early detection of melanoma.
Australia and The Netherlands have an alarming statistic in common – melanoma is in their top five most diagnosed cancers. Clinical teams from both countries are now contributing to the international MelMarT-II trial.
A community fundraising campaign has donated $100,000 to a clinical trial investigating melanoma that has spread to the brain.
MASC Trials and Melanoma Patients Australia have launched Self-Skin Checks, No Regrets, an Australian first campaign targeting rural and regional Australians 60+ to regularly check their skin.
An Australian-led trial is now gathering melanoma experts from around the world to contribute results from 3,000 patients to determine the optimal surgical excision margin for melanoma of the skin.
Leading Merkel cell carcinoma expert, Dr Wen Xu, recently presented two Australian clinical trials at the 2nd International Symposium of Merkel Cell Carcinoma in Seattle, USA.
The I-MAT clinical trial is giving patients with early-stage Merkel cell carcinoma an immunotherapy drug after their initial surgery and / or radiotherapy for the cancer to improve their cure rates.